Letters to the Editor

Standardization of flow cytometric minimal residual disease assessment in international clinical trials - a feasibility study from the European Myeloma Network

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; Laboratory Medical Immunology, Department of Immunology, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands
Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy
Department of Hematology, University Hospital Brno, Brno, Czech Republic
Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark
Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy
Laboratory Medical Immunology, Department of Immunology, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands
Department of Hematology, University Hospital Brno, Brno, Czech Republic
Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark
Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark
Department of Hemato-oncology, University Hospital Ostrava and Faculty of Medicine, Ostrava University, Ostrava, Czech Republic
Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy
Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy
Laboratory Medical Immunology, Department of Immunology, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands
Haematologica Early view Oct 5, 2020 https://doi.org/10.3324/haematol.2020.267831